News - Pharmaceuticals
AbbVie New Zealand welcomes new leadership as global moves unfold

Pharma News: AbbVie has announced the appointment of Elhussein Abdellatif as the new Country Head for New Zealand. Reporting directly to Nathalie McNeil, Vice President and General Manager of AbbVie Australia & New Zealand, Hussein brings a wealth of experience and expertise to his new role.
Hussein takes over from Kylie Pennington, who has been at the helm of AbbVie New Zealand since May 2022. Kylie has been appointed General Manager for Skyrizi Dermatology, International Marketing & Commercial Operations (IMCO), reporting to Felipe Palacios, VP, Immunology, IMCO.
With a degree in Pharmaceutical Science from Ain Shams University in Egypt and over 18 years of industry experience spanning various roles and therapeutic areas, including Immunology, Oncology, Neuroscience, and HCV, Hussein is well-equipped to lead the New Zealand team.
Having been with AbbVie for nine years, Hussein initially joined AbbVie Saudi Arabia in 2015, progressing through the ranks. His most recent role was as the Oncology Commercial Director, Intercontinental, based in the US. Prior to joining AbbVie, Hussein gained valuable experience at MSD, Lundbeck, and Novartis, where he held roles in sales and marketing.
Ms McNeil expressed enthusiasm about Hussein’s appointment, stating, “We are excited to have Hussein join and lead the New Zealand team to build on the strong foundations already in place. His promotion, along with Kylie’s promotion to a global role, demonstrates AbbVie’s commitment to developing key talent and creating compelling career opportunities. We also thank Kylie for her leadership over the past two years in the Country Head role.”
Hussein officially assumed his new role last month and is currently in the process of relocating from Chicago to New Zealand with his family. In a parallel move, Kylie Pennington and her family are also relocating, making the journey from Auckland to Chicago.
In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News - MedTech & Diagnostics
Hearts4heart takes aim at health insurers leaving patients to pay the price
Persistent advocacy by patient groups has prompted the Medical Services Advisory Committee (MSAC) to review the funding gaps for pulsed […]
MoreNews - MedTech & Diagnostics
Queensland first: Private hospitals deploy Abbott’s PFA in atrial fibrillation
More Australians living with atrial fibrillation (AF) are gaining access to one of the latest advances in heart-rhythm treatment, with […]
MoreNews - Pharmaceuticals
Five years of HTA reform talk, now comes the $47 billion question
Medicines Australia has put a $47 billion price tag on what it says Australia must invest to improve equitable access […]
MoreNews - Pharmaceuticals
New MFN deals raise the stakes for Australia’s delayed HTA reform
Four months after the US Trump administration concluded what was expected to be the final tranche of drug-pricing agreements with […]
More